دورية أكاديمية
أعرض في EDS

Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression.

التفاصيل البيبلوغرافية
العنوان: Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression.
المؤلفون: Lutgendorf SK; Department of Psychological and Brain Sciences, University of Iowa, Iowa City, Iowa, USA.; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa, Iowa City, Iowa, USA., Thaker PH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, USA., Goodheart MJ; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa, Iowa City, Iowa, USA., Arevalo JMG; Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA., Chowdhury MA; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Noble AE; Department of Psychological and Brain Sciences, University of Iowa, Iowa City, Iowa, USA., Dahmoush L; Department of Pathology, University of Iowa, Iowa City, Iowa, USA., Slavich GM; Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, California, USA.; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, USA., Penedo FJ; Department of Psychology and Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA., Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Center for RNA Interference and Noncoding RNA, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Cole SW; Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.; Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, California, USA.; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, USA.
المصدر: Cancer [Cancer] 2022 Dec 01; Vol. 128 (23), pp. 4157-4165. Date of Electronic Publication: 2022 Oct 17.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005- >: Hoboken, NJ : Wiley
Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.]
مواضيع طبية MeSH: Exosomes*/genetics , Exosomes*/metabolism , Ovarian Neoplasms*/pathology , Carcinoma*, Humans ; Female ; Carcinoma, Ovarian Epithelial ; Biomarkers/metabolism ; RNA/metabolism ; RNA/therapeutic use ; Disease Progression
مستخلص: Background: Biobehavioral factors such as social isolation and depression have been associated with disease progression in ovarian and other cancers. Here, the authors developed a noninvasive, exosomal RNA profile for predicting ovarian cancer disease progression and subsequently tested whether it increased in association with biobehavioral risk factors.
Methods: Exosomes were isolated from plasma samples from 100 women taken before primary surgical resection or neoadjuvant (NACT) treatment of ovarian carcinoma and 6 and 12 months later. Biobehavioral measures were sampled at all time points. Plasma from 76 patients was allocated to discovery analyses in which morning presurgical/NACT exosomal RNA profiles were analyzed by elastic net machine learning to identify a biomarker predicting rapid (≤6 months) versus more extended disease-free intervals following initial treatment. Samples from a second subgroup of 24 patients were analyzed by mixed-effects linear models to determine whether the progression-predictive biomarker varied longitudinally as a function of biobehavioral risk factors (social isolation and depressive symptoms).
Results: An RNA-based molecular signature was identified that discriminated between individuals who had disease progression in ≤6 months versus >6 months, independent of clinical variables (age, disease stage, and grade). In a second group of patients analyzed longitudinally, social isolation and depressive symptoms were associated with upregulated expression of the disease progression propensity biomarker, adjusting for covariates.
Conclusion: These data identified a novel exosome-derived biomarker indicating propensity of ovarian cancer progression that is sensitive to biobehavioral variables. This derived biomarker may be potentially useful for risk assessment, intervention targeting, and treatment monitoring.
(© 2022 American Cancer Society.)
References: Clin Cancer Res. 2008 Nov 1;14(21):6839-46. (PMID: 18980978)
Br J Cancer. 2021 Mar;124(7):1286-1293. (PMID: 33473167)
Cancer. 2020 Oct 1;126(19):4407-4413. (PMID: 32691853)
Psychol Aging. 1997 Jun;12(2):277-87. (PMID: 9189988)
J Ovarian Res. 2021 Feb 7;14(1):27. (PMID: 33550985)
Nat Rev Dis Primers. 2016 Aug 25;2:16061. (PMID: 27558151)
Gynecol Oncol. 2008 Jul;110(1):13-21. (PMID: 18589210)
Breast Cancer Res Treat. 2017 Aug;165(1):169-180. (PMID: 28560656)
Sci Transl Med. 2020 Dec 2;12(572):. (PMID: 33268511)
Mol Ther Nucleic Acids. 2018 Mar 2;10:131-141. (PMID: 29499928)
Int J Mol Sci. 2021 Feb 22;22(4):. (PMID: 33671587)
J Clin Oncol. 2012 Aug 10;30(23):2885-90. (PMID: 22802321)
Int J Mol Sci. 2020 Dec 01;21(23):. (PMID: 33271935)
Front Oncol. 2012 Apr 17;2:38. (PMID: 22649786)
Obstet Gynecol. 2018 Sep;132(3):545-554. (PMID: 30095787)
Mol Cancer. 2019 Aug 13;18(1):124. (PMID: 31409361)
Int J Mol Sci. 2020 Nov 19;21(22):. (PMID: 33228245)
Cell Rep. 2020 Apr 14;31(2):107502. (PMID: 32294438)
Crit Rev Oncol Hematol. 2010 Aug;75(2):122-37. (PMID: 19604706)
Mol Cell Oncol. 2016 May 31;3(4):e1177674. (PMID: 27652324)
J Psychosom Res. 1999 May;46(5):437-43. (PMID: 10404478)
Mol Cancer. 2017 May 15;16(1):92. (PMID: 28506269)
PLoS One. 2012;7(8):e42324. (PMID: 22870317)
Anal Cell Pathol (Amst). 2020 Dec 12;2020:8984526. (PMID: 33489719)
J Clin Invest. 2013 Feb;123(2):874-86. (PMID: 23348742)
Brain Behav Immun. 2011 Feb;25(2):250-5. (PMID: 20955777)
Cancer. 2018 Feb 1;124(3):580-586. (PMID: 29112229)
Brain Behav Immun. 2013 Mar;30 Suppl:S26-31. (PMID: 23164950)
Brain Behav Immun. 2009 Feb;23(2):176-83. (PMID: 18550328)
J Clin Oncol. 2010 Sep 10;28(26):4094-9. (PMID: 20644093)
Cancer. 2009 Nov 15;115(22):5349-61. (PMID: 19753617)
Science. 2020 Feb 7;367(6478):. (PMID: 32029601)
Science. 2019 Nov 22;366(6468):965. (PMID: 31753994)
JNCI Cancer Spectr. 2018 Jul;2(3):pky029. (PMID: 30057973)
J Behav Med. 2015 Feb;38(1):48-56. (PMID: 24935017)
Gynecol Oncol. 2008 Dec;111(3):478-86. (PMID: 18823650)
Psychol Med. 2010 Nov;40(11):1797-810. (PMID: 20085667)
Cancer Res. 2010 Mar 15;70(6):2296-306. (PMID: 20215510)
Nat Rev Cancer. 2015 Sep;15(9):563-72. (PMID: 26299593)
Oncol Lett. 2021 Mar;21(3):185. (PMID: 33574924)
Gynecol Oncol. 2009 Oct;115(1):112-120. (PMID: 19647308)
Cancer. 2019 May 1;125(9):1417-1431. (PMID: 30768779)
Nat Rev Cancer. 2021 Dec;21(12):767-785. (PMID: 34508247)
Cancer Res. 2010 Sep 15;70(18):7042-52. (PMID: 20823155)
معلومات مُعتمدة: R35 CA209904 United States CA NCI NIH HHS; P30CA086862 United States CA NCI NIH HHS; R01 CA193249 United States CA NCI NIH HHS; CA109298 United States CA NCI NIH HHS; R01 CA140933 United States CA NCI NIH HHS; CA209904 United States CA NCI NIH HHS; P30 CA086862 United States CA NCI NIH HHS; R01 CA109298 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: biobehavioral; exosome; ovarian cancer; progression; social support; transcriptome
المشرفين على المادة: 0 (Biomarkers)
63231-63-0 (RNA)
تواريخ الأحداث: Date Created: 20221017 Date Completed: 20221118 Latest Revision: 20231202
رمز التحديث: 20231202
مُعرف محوري في PubMed: PMC9744596
DOI: 10.1002/cncr.34496
PMID: 36251340
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-0142
DOI:10.1002/cncr.34496